{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:15:48Z","timestamp":1791292548496,"version":"4.1.0"},"reference-count":98,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The use of allogeneic hematopoietic cell transplantation (HCT) has expanded progressively, facilitated by the increasing availability of unrelated donors and cord blood, and the inclusion of older patients as transplantation candidates. Indications remain diagnosis-dependent. As novel nontransplantation modalities have been developed concurrently, many patients come to HCT only when no longer responding to such therapy. However, patients with refractory or advanced disease frequently relapse after HCT, even with high-dose conditioning, and more so with reduced-intensity regimens as used for patients of older age or with comorbid conditions. Thus, patients with high-risk malignancies who have substantial comorbidities or are of advanced age are at high risk of both relapse and nonrelapse mortality and should probably not be transplanted. Being in remission or at least having shown responsiveness to pre-HCT therapy is generally associated with increased transplantation success. In addition, to handle the stress associated with HCT, patients need a good social support system and a secure financial net. They must be well informed, not only about the transplantation process, but also about expected or potential post-HCT events, including graft-versus-host disease and delayed effects that may become manifest only years after HCT.<\/jats:p>","DOI":"10.1182\/blood-2010-07-259358","type":"journal-article","created":{"date-parts":[[2010,8,11]],"date-time":"2010-08-11T23:06:11Z","timestamp":1281567971000},"page":"4762-4770","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":93,"title":["Who is fit for allogeneic transplantation?"],"prefix":"10.1182","volume":"116","author":[{"given":"H. Joachim","family":"Deeg","sequence":"first","affiliation":[{"name":"Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda M.","family":"Sandmaier","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2019111807203429300_B1","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2002-08-2628","article-title":"Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.","volume":"102","author":"Mielcarek","year":"2003","journal-title":"Blood"},{"key":"2019111807203429300_B2","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.coi.2008.06.014","article-title":"Optimal HLA matching in hematopoietic cell transplantation.","volume":"20","author":"Petersdorf","year":"2008","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"2019111807203429300_B3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1365-2141.2009.07883.x","article-title":"Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors.","volume":"147","author":"Rocha","year":"2009","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111807203429300_B4","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nrc1125","article-title":"Umbilical-cord blood transplantation for the treatment of cancer [review].","volume":"3","author":"Barker","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"2019111807203429300_B5","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1182\/blood-2008-02-140095","article-title":"A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation.","volume":"112","author":"Ciceri","year":"2008","journal-title":"Blood"},{"key":"2019111807203429300_B6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclophosphamide.","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111807203429300_B7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1056\/NEJM200101183440303","article-title":"Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.","volume":"344","author":"Bensinger","year":"2001","journal-title":"N Engl J Med"},{"issue":"13","key":"2019111807203429300_B8","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1182\/blood-2006-05-024042","article-title":"Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.","volume":"108","author":"Schmitz","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2019111807203429300_B9","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1200\/JCO.1996.14.1.220","article-title":"Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors.","volume":"14","author":"Anderson","year":"1996","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111807203429300_B10","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia.","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"issue":"3","key":"2019111807203429300_B11","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"issue":"8","key":"2019111807203429300_B12","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1182\/blood.V89.8.3048","article-title":"Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation.","volume":"89","author":"Storb","year":"1997","journal-title":"Blood"},{"issue":"6","key":"2019111807203429300_B13","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bbmt.2009.03.007","article-title":"Transplant conditioning regimens: can we say it better? [editorial].","volume":"15","author":"Deeg","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111807203429300_B14","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/sj.leu.2404327","article-title":"Optimization of allogeneic transplant conditioning: not the time for dogma.","volume":"20","author":"Deeg","year":"2006","journal-title":"Leukemia"},{"issue":"3","key":"2019111807203429300_B15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbmt.2006.10.017","article-title":"Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.","volume":"13","author":"Russell","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2019111807203429300_B16","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1182\/blood.V98.10.2942","article-title":"Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO).","volume":"98","author":"Bacigalupo","year":"2001","journal-title":"Blood"},{"issue":"11","key":"2019111807203429300_B17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood.V104.11.181.181","article-title":"Reduced incidence of acute and chronic graft-versus-host disease (GvHD) without increased relapse in patients with high-risk myeloid disorders given thymoglobulin (THY) as part of the transplant conditioning regimen: a dose finding study [abstract].","volume":"104","author":"Deeg","year":"2004","journal-title":"Blood"},{"issue":"5","key":"2019111807203429300_B18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/sj.bmt.1703374","article-title":"Association between pretransplant thymogloblulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors.","volume":"29","author":"Remberger","year":"2002","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2019111807203429300_B19","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions.","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"2019111807203429300_B20","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1200\/JCO.2006.06.9914","article-title":"Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopietic cell transplantation.","volume":"24","author":"Baron","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111807203429300_B21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.bmt.1703606","article-title":"Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant.","volume":"30","author":"Martino","year":"2002","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2019111807203429300_B22","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2003-11-3750","article-title":"Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation.","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"issue":"3","key":"2019111807203429300_B23","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/blood-2005-11-4503","article-title":"Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.","volume":"108","author":"Martino","year":"2006","journal-title":"Blood"},{"key":"2019111807203429300_B24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/sj.leu.2404010","article-title":"Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis.","volume":"20","author":"Scott","year":"2006","journal-title":"Leukemia"},{"issue":"9","key":"2019111807203429300_B25","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","article-title":"Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.","volume":"102","author":"Maloney","year":"2003","journal-title":"Blood"},{"key":"2019111807203429300_B26","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/9781444303537.ch105","article-title":"Delayed nonmalignant complications after hematopoietic cell transplantation.","volume-title":"Thomas' Hematopoietic Cell Transplantation","author":"Flowers","year":"2009"},{"issue":"1","key":"2019111807203429300_B27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bbmt.2006.10.020","article-title":"Transplantation's greatest challenges: advances in chronic graft-versus-host disease [review].","volume":"13","author":"Shlomchik","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2019111807203429300_B28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.bmt.1705963","article-title":"Searching for alternative hematopoietic stem cell donors for pediatric patients [review].","volume":"41","author":"Rocha","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"2019111807203429300_B29","first-page":"193","article-title":"Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate\/cyclosporine prophylaxis.","volume":"7","author":"Deeg","year":"1991","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2019111807203429300_B30","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/blood.V76.9.1867.1867","article-title":"Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens.","volume":"76","author":"Clift","year":"1990","journal-title":"Blood"},{"key":"2019111807203429300_B31","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1365-2141.1990.tb06340.x","article-title":"Previous donor pregnancy as a risk factor for acute graft-versus-host disease in patients with aplastic anaemia treated by allogeneic marrow transplantation.","volume":"74","author":"Flowers","year":"1990","journal-title":"Br J Haematol"},{"key":"2019111807203429300_B32","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2141.1987.tb06160.x","article-title":"Risk factors for acute graft-versus-host disease.","volume":"67","author":"Gale","year":"1987","journal-title":"Br J Haematol"},{"key":"2019111807203429300_B33","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2010.05.006","article-title":"Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation.","author":"Rotta","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"2019111807203429300_B34","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: a systematic review and meta-analysis of prospective clinical trials.","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA"},{"issue":"1","key":"2019111807203429300_B35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ije\/dyg313","article-title":"Mendelian randomization: an update on its use to evaluate allogeneic stem cell transplantation in leukaemia [commentary].","volume":"33","author":"Wheatley","year":"2004","journal-title":"Int J Epidemiol"},{"issue":"17","key":"2019111807203429300_B36","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1200\/JCO.2009.27.1460","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.","volume":"28","author":"Gyurkocza","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111807203429300_B37","article-title":"Bone marrow transplantation with HLA identical donors in the acute leukemias: Baltimore experience.","volume-title":"Minimal Residual Disease in Acute Leukemia","author":"Santos","year":"1986"},{"key":"2019111807203429300_B38","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1200\/JCO.1992.10.11.1723","article-title":"Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia.","volume":"10","author":"Clift","year":"1992","journal-title":"J Clin Oncol"},{"key":"2019111807203429300_B39","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood.V63.3.649.bloodjournal633649","article-title":"Allogeneic bone marrow transplantation for patients with acute nonlymphocytic leukemia.","volume":"63","author":"Dinsmore","year":"1984","journal-title":"Blood"},{"issue":"18","key":"2019111807203429300_B40","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.","volume":"358","author":"Schlenk","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111807203429300_B41","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1182\/blood-2005-12-4938","article-title":"Role of allogeneic stem cell transplantation in FLT3\/ITD-positive AML [letter].","volume":"108","author":"Meshinchi","year":"2006","journal-title":"Blood"},{"issue":"12","key":"2019111807203429300_B42","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1182\/blood-2006-03-009233","article-title":"Clinical implications of FLT3 mutations in pediatric AML.","volume":"108","author":"Meshinchi","year":"2006","journal-title":"Blood"},{"key":"2019111807203429300_B43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/asheducation-2006.1.133","article-title":"Treatment of adult acute lymphoblastic leukemia.","author":"Gokbuget","year":"2006","journal-title":"Hematology"},{"issue":"5","key":"2019111807203429300_B44","first-page":"1556","article-title":"A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.","volume":"92","author":"Larson","year":"1998","journal-title":"Blood"},{"issue":"4","key":"2019111807203429300_B45","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","article-title":"In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII\/ECOG E2993).","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"issue":"19","key":"2019111807203429300_B46","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1182\/blood-2009-01-199380","article-title":"Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII\/ECOG2993.","volume":"113","author":"Fielding","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111807203429300_B47","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood-2007-07-098483","article-title":"Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative regimens for treatment of lymphoma and chronic lymphocytic leukemia.","volume":"111","author":"Sorror","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2019111807203429300_B48","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2019111807203429300_B49","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin lymphoma.","volume":"28","author":"Rezvani","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111807203429300_B50","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"issue":"6","key":"2019111807203429300_B51","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","article-title":"The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"issue":"9","key":"2019111807203429300_B52","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2005-08-3453","article-title":"Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia.","volume":"107","author":"Stirewalt","year":"2006","journal-title":"Blood"},{"issue":"12","key":"2019111807203429300_B53","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1182\/blood-2009-09-241075","article-title":"Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.","volume":"115","author":"Pollard","year":"2010","journal-title":"Blood"},{"issue":"24","key":"2019111807203429300_B54","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1200\/JCO.2006.06.9500","article-title":"Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.","volume":"24","author":"Paschka","year":"2006","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111807203429300_B55","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrc1169","article-title":"The role of FLT3 in haematopoietic malignancies [review].","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2019111807203429300_B56","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.2009.21.8073","article-title":"Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia.","volume":"28","author":"Lim","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111807203429300_B57","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","article-title":"Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.","volume":"28","author":"McClune","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111807203429300_B58","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia.","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"2019111807203429300_B59","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/clpt.1986.204","article-title":"Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients.","volume":"40","author":"Yee","year":"1986","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"2019111807203429300_B60","first-page":"617","article-title":"Renal function and functional reserve in healthy elderly individuals.","volume":"20","author":"Esposito","year":"2007","journal-title":"J Nephrol"},{"issue":"7","key":"2019111807203429300_B61","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.bbmt.2010.02.006","article-title":"Chronic kidney disease, thrombotic microangiopathy, and hypertension following T cell-depleted hematopoietic stem cell transplantation.","volume":"16","author":"Glezerman","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111807203429300_B62","first-page":"423","article-title":"Bone marrow transplantation for Fanconi's anaemia: conditioning with reduced doses of cyclophosphamide without radiation.","volume":"94","author":"Dokal","year":"1996","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111807203429300_B63","doi-asserted-by":"crossref","first-page":"407","DOI":"10.7326\/0003-4819-144-6-200603210-00007","article-title":"A risk score for mortality after allogeneic hematopoietic cell transplantation.","volume":"144","author":"Parimon","year":"2006","journal-title":"Ann Intern Med"},{"issue":"8","key":"2019111807203429300_B64","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"2019111807203429300_B65","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.bbmt.2005.05.008","article-title":"Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia.","volume":"11","author":"Kerbauy","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"27","key":"2019111807203429300_B66","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.2006.09.7865","article-title":"Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.","volume":"25","author":"Sorror","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111807203429300_B67","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/bmt.2009.236","article-title":"Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML.","volume":"45","author":"Lim","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2019111807203429300_B68","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1182\/blood.V112.11.4295.4295","article-title":"Pre-transplant comorbidity as an outcome predictor in hematopoietic cell transplantation for severe aplastic anemia [abstract].","volume":"112","author":"Lim","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2019111807203429300_B69","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/leu.2009.1","article-title":"The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.","volume":"23","author":"Farina","year":"2009","journal-title":"Leukemia"},{"issue":"9","key":"2019111807203429300_B70","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.bbmt.2008.06.019","article-title":"Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myeloma.","volume":"14","author":"Labont\u00e9","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2019111807203429300_B71","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/bmt.2008.300","article-title":"Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center.","volume":"43","author":"Guilfoyle","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2019111807203429300_B72","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.bbmt.2010.02.004","article-title":"Prognostic factor and quality of life analysis in 160 patients aged > or = to 60 years with hematologic neoplasias treated with allogeneic hematopoietic cell transplantation.","volume":"16","author":"Deschler","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111807203429300_B73","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.bbmt.2008.12.509","article-title":"Carbon monoxide diffusion capacity: how long can you go for hematopoietic cell transplantation eligibility?","volume":"15","author":"Chien","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111807203429300_B74","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.bbmt.2009.11.008","article-title":"Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut points to determine low, intermediate and high risk groups: the flexible HCT-CI is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.","volume":"16","author":"Barba","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111807203429300_B75","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2008.197","article-title":"Impact of comorbidity indexes on non-relapse mortality.","volume":"22","author":"Xhaard","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"2019111807203429300_B76","first-page":"461","article-title":"Impact of patient weight on non-relapse mortality after marrow transplantation.","volume":"15","author":"Deeg","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2019111807203429300_B77","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood.V92.2.394","article-title":"Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase.","volume":"92","author":"Morton","year":"1998","journal-title":"Blood"},{"issue":"3","key":"2019111807203429300_B78","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0002-9343(96)00450-0","article-title":"Impact of obesity on allogeneic stem cell transplant patients: a matched case-controlled study.","volume":"102","author":"Fleming","year":"1997","journal-title":"Am J Med"},{"issue":"6","key":"2019111807203429300_B79","first-page":"607","article-title":"Body weight and outcome of hematopoietic stem cell transplantation [letter].","volume":"104","author":"Deeg","year":"1998","journal-title":"Am J Med"},{"issue":"14","key":"2019111807203429300_B80","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1056\/NEJM199804023381405","article-title":"Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia.","volume":"338","author":"Hansen","year":"1998","journal-title":"N Engl J Med"},{"key":"2019111807203429300_B81","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00007890-198803000-00029","article-title":"Effect of obesity on cyclosporine disposition.","volume":"45","author":"Yee","year":"1988","journal-title":"Transplantation"},{"issue":"19","key":"2019111807203429300_B82","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1001\/jama.291.19.2335","article-title":"Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma.","volume":"291","author":"Syrjala","year":"2004","journal-title":"JAMA"},{"key":"2019111807203429300_B83","volume-title":"Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care","year":"2003"},{"issue":"12","key":"2019111807203429300_B84","first-page":"1321","article-title":"Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea.","volume":"2","author":"Kreklau","year":"2003","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"2019111807203429300_B85","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1200\/JCO.1997.15.7.2644","article-title":"Access to bone marrow transplantation for leukemia and lymphoma: the role of sociodemographic factors.","volume":"15","author":"Mitchell","year":"1997","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111807203429300_B86","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bbmt.2006.12.056","article-title":"Access to hematopoietic stem cell transplantation: effect of race and gender [abstract].","volume":"13","author":"Joshua","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2019111807203429300_B87","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/cncr.20628","article-title":"Hematopoietic stem cell transplantation among patients with leukemia of all ages in Texas.","volume":"101","author":"Hwang","year":"2004","journal-title":"Cancer"},{"issue":"12","key":"2019111807203429300_B88","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.bbmt.2009.07.023","article-title":"Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation.","volume":"15","author":"Baker","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111807203429300_B89","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bbmt.2004.12.327","article-title":"Effects of race on survival after stem cell transplantation.","volume":"11","author":"Mielcarek","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111807203429300_B90","first-page":"87","article-title":"Is race a risk factor for allogeneic marrow transplantation?","volume":"1","author":"Klingemann","year":"1986","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2019111807203429300_B91","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1056\/NEJMp0912062","article-title":"Medicare and medical technology: the growing demand for relevant outcomes.","volume":"362","author":"Neumann","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111807203429300_B92","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.bbmt.2009.12.529","article-title":"Access to hematopoietic cell transplantation in the United States.","volume":"16","author":"Majhail","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2019111807203429300_B93","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2004-01-0200","article-title":"Duration of immunosuppressive treatment for chronic graft-versus-host disease.","volume":"104","author":"Stewart","year":"2004","journal-title":"Blood"},{"issue":"17","key":"2019111807203429300_B94","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood-2009-06-229369","article-title":"Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study.","volume":"116","author":"Sun","year":"2010","journal-title":"Blood"},{"key":"2019111807203429300_B95","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.bbmt.2005.12.036","article-title":"Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan\/cyclophosphamide regimen.","volume":"12","author":"Deeg","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2019111807203429300_B96","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.bbmt.2007.12.314","article-title":"Effect of substituting fludarabine and thymoglobulin for cyclophosphamide in busulfan-based conditioning regimens on T-cell chimerism and outcomes after allogeneic hematopoietic cell transplantation (HCT) [abstract].","volume":"14","author":"O'Donnell","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111807203429300_B97","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.bbmt.2007.11.012","article-title":"Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.","volume":"14","author":"Laport","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"17","key":"2019111807203429300_B98","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1056\/NEJMoa0802629","article-title":"Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation.","volume":"359","author":"Bochud","year":"2008","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/116\/23\/4762\/1331986\/zh804910004762.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/116\/23\/4762\/1331986\/zh804910004762.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T05:27:35Z","timestamp":1591766855000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/116\/23\/4762\/28280\/Who-is-fit-for-allogeneic-transplantation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,2]]},"references-count":98,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2010,12,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2010-07-259358","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,2]]}}}